成大生物：已经完成了15价HPV疫苗的技术转移和工艺复现

Core Viewpoint - The company has clarified its collaboration agreement with Kang Le Wei Shi, outlining the rights, obligations, and project arrangements for both parties [1] Group 1 - The company has completed the technology transfer and process replication for the 15-valent HPV vaccine, demonstrating its capability to independently advance subsequent research and development [1] - The company commits to timely information disclosure in accordance with listing rules in the event of any significant progress or changes [1]